6-K ·Filed Mar 30, 2026

MDWD

MediWound Ltd.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001178913-26-001859
Notable filing: 6-K
Actionable Insight • Neutral

This is a routine governance filing with no immediate trading implications. Traders should monitor for any unexpected developments during the meeting or in the voting results, but no significant stock price movement is expected from this announcement alone.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
MDWD ▼ -5.71% at T+60d
NEUTRAL call ✗ call lost -5.71% · α vs SPY -18.09% · entry $16.11 → $15.19
Entry anchored
Mar 30, 03:59 PM ET
via exchange tick
T+1d
+0.56%
call +0.56% · α -0.19%
$16.20
settled 6mo ago
T+5d
+7.20%
call +7.20% · α +3.26%
$17.27
settled 6mo ago
T+20d
+1.52%
call +1.52% · α -7.90%
$16.36
settled 5mo ago
T+60d
-5.71%
call -5.71% · α -18.09%
$15.19
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

MediWound Ltd. (MDWD) has issued a 6-K filing to announce its 2026 Annual General Meeting of Shareholders, scheduled for May 6, 2026. The meeting will address the re-election of five board members, reappointment of the independent auditor Somekh Chaikin (KPMG), and approval of a $206,000 cash bonus for CEO Ofer Gonen for 2025 performance. This is a routine corporate governance filing with no immediate financial impact.

Key Facts

  • Annual General Meeting scheduled for May 6, 2026
  • Proposals include re-election of 5 directors: Nachum Shamir, Vickie R. Driver, David Fox, Shmuel Rubinstein, and Stephen T. Wills
  • Reappointment of Somekh Chaikin (KPMG) as independent auditor for 2026
  • Proposal to approve $206,000 cash bonus for CEO Ofer Gonen for 2025 performance
  • Record date for voting is March 31, 2026
  • Board unanimously recommends approval of all proposals

Financial Impact

Approximately $206,000 cash bonus for CEO if approved

executive compensationgeneral and administrative expenses

Risk Factors

  • Potential shareholder opposition to CEO bonus approval, though unlikely given board recommendation
  • Low voter turnout could affect quorum requirements

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-001859
Exhibit: exhibit_99-2.htm0001178913-26-001859
Document: zk2634988.htm0001178913-26-001859
Document: 0001178913-26-001859-index-headers.html0001178913-26-001859
Document: 0001178913-26-001859-index.html0001178913-26-001859
Document: 0001178913-26-001859.txt0001178913-26-001859
6 reports for MDWD
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +20.80%Mar 5, 2026
Filters
Rows
Reports for MDWD — sortable, filterable
TypeNow
Jun 2, 2026
17w ago
Insider Cluster
BULLISH ★ 4/10
$13.76 $12.70▼ −7.70%▼ −8.82%$13.52 (−1.74%)
May 27, 2026
18w ago
Press Release
BEARISH ★ 6/10
$14.33 $13.12▲ +8.48%▲ +10.36%$13.52 (+5.65%)
May 7, 2026
21w ago
Press Release
NEUTRAL ★ 2/10
$17.27 $14.22▼ −17.66%▼ −21.49%$13.52 (−21.71%)
Mar 30, 2026
26w ago
6-K
NEUTRAL ★ 2/10
$16.11 $15.19▼ −5.71%▼ −18.09%$13.52 (−16.08%)
Mar 5, 2026
30w ago
Press Release
NEUTRAL ★ 3/10
$17.03 $13.82▼ −18.85%▼ −31.63%$13.52 (−20.61%)
Mar 5, 2026
30w ago
Press Release
BEARISH ★ 6/10
$17.45 $13.82▲ +20.80%▲ +32.10%$13.52 (+22.52%)
Showing 6 of 6

US Market Status

Market Closed — Opens Mon (38h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access